Antisense startup Stoke Therapeutics secures another $90M in series B funding

Antisense startup Stoke Therapeutics secures another $90M in series B funding

Source: 
Endpoints
snippet: 


Led by former Sarepta CEO, antisense startup Stoke Therapeutics has raked in $90 million in series B financing, following up the $40 million announced earlier this year.